AI assistant
SUTRO BIOPHARMA, INC. — Director's Dealing 2021
Nov 22, 2021
34319_dirs_2021-11-22_54abbb62-2e77-4e6c-badb-6b50d8e44cea.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: SUTRO BIOPHARMA, INC. (STRO)
CIK: 0001382101
Period of Report: 2021-11-19
Reporting Person: Hunter Heidi (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-11-19 | Stock Option (right to buy Common Stock) | $17.56 | A | 24000 | Acquired | 2031-11-18 | Common Stock (24000) | Direct |
| 2021-11-19 | Stock Option (right to buy Common Stock) | $17.56 | A | 9884 | Acquired | 2031-11-18 | Common Stock (9884) | Direct |
Footnotes
F1: The option vests as to 2.778% of the total shares monthly, beginning on December 19, 2021, with 100% of the total shares vested and exercisable on November 19, 2024, subject to the reporting person's provision of service to the issuer on each vesting date.
F2: The option vests as to 15.59% of the total shares monthly beginning on December 19, 2021 through May 19, 2022, and 6.45% on June 2, 2022, with 100% of the total shares vested and exercisable on the issuer's 2022 annual meeting of stockholders, subject to the reporting person's provision of service to the issuer on each vesting date.